Used as a key intermediate in the synthesis of anti-tuberculosis agents, particularly in the development of Delamanid (OPC-67683), a nitro-dihydro-imidazooxazole drug for treating multi-drug resistant tuberculosis (MDR-TB). Its chiral structure enables selective interactions with biological targets in Mycobacterium tuberculosis, enhancing drug efficacy against cell wall synthesis. The compound's nitro and hydroxyl functional groups allow further chemical modifications, making it valuable in medicinal chemistry for building complex pharmacophores. It is primarily employed in research settings to design novel therapeutics targeting drug-resistant TB strains.